naa a22 4500 510764398 CHVBK 20180411083151.0 cr unu---uuuuu 180411e20130201xx s 000 0 eng 10.1007/s12094-012-0926-8 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0926-8 MYC oncogene in myeloid neoplasias [Elektronische Daten] [M. Delgado, Marta Albajar, M. Gomez-Casares, Ana Batlle, Javier León] MYC is a transcription factor that regulates many critical genes for cell proliferation, differentiation, and biomass accumulation. MYC is one of the most prevalent oncogenes found to be altered in human cancer, being deregulated in about 50% of tumors. Although MYC deregulation has been more frequently associated to lymphoma and lymphoblastic leukemia than to myeloid malignancies, a body of evidence has been gathered showing that MYC plays a relevant role in malignancies derived from the myeloid compartment. The myeloid leukemogenic activity of MYC has been demonstrated in different murine models. Not surprisingly, MYC has been found to be amplified or/and deregulated in the three major types of myeloid neoplasms: acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms, including chronic myeloid leukemia. Here, we review the recent literature describing the involvement of MYC in myeloid tumors. Federación de Sociedades Españolas de Oncología (FESEO), 2012 MYC nationallicence Myeloid neoplasia nationallicence Acute myeloid leukemia nationallicence Chronic myeloid leukemia nationallicence Myelodysplastic syndromes nationallicence Delgado M. Group of Transcriptional Control and Cancer, Departamento de Biología Molecular, Facultad de Medicina, Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria, CSIC, SODERCAN, Avda Cardenal Herrera Oria s/n, 39011, Santander, Spain aut Albajar Marta Group of Transcriptional Control and Cancer, Departamento de Biología Molecular, Facultad de Medicina, Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria, CSIC, SODERCAN, Avda Cardenal Herrera Oria s/n, 39011, Santander, Spain aut Gomez-Casares M. Servicio de Hematología and Unidad de Investigación, Hospital Dr. Negrín, Las Palmas, Spain aut Batlle Ana Group of Transcriptional Control and Cancer, Departamento de Biología Molecular, Facultad de Medicina, Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria, CSIC, SODERCAN, Avda Cardenal Herrera Oria s/n, 39011, Santander, Spain aut León Javier Group of Transcriptional Control and Cancer, Departamento de Biología Molecular, Facultad de Medicina, Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria, CSIC, SODERCAN, Avda Cardenal Herrera Oria s/n, 39011, Santander, Spain aut Clinical and Translational Oncology Springer Milan 15/2(2013-02-01), 87-94 1699-048X 15:2<87 2013 15 12094 https://doi.org/10.1007/s12094-012-0926-8 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0926-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Delgado M. Group of Transcriptional Control and Cancer, Departamento de Biología Molecular, Facultad de Medicina, Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria, CSIC, SODERCAN, Avda Cardenal Herrera Oria s/n, 39011, Santander, Spain aut NATIONALLICENCE 700 1- Albajar Marta Group of Transcriptional Control and Cancer, Departamento de Biología Molecular, Facultad de Medicina, Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria, CSIC, SODERCAN, Avda Cardenal Herrera Oria s/n, 39011, Santander, Spain aut NATIONALLICENCE 700 1- Gomez-Casares M. Servicio de Hematología and Unidad de Investigación, Hospital Dr. Negrín, Las Palmas, Spain aut NATIONALLICENCE 700 1- Batlle Ana Group of Transcriptional Control and Cancer, Departamento de Biología Molecular, Facultad de Medicina, Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria, CSIC, SODERCAN, Avda Cardenal Herrera Oria s/n, 39011, Santander, Spain aut NATIONALLICENCE 700 1- León Javier Group of Transcriptional Control and Cancer, Departamento de Biología Molecular, Facultad de Medicina, Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria, CSIC, SODERCAN, Avda Cardenal Herrera Oria s/n, 39011, Santander, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/2(2013-02-01), 87-94 1699-048X 15:2<87 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer